Search details
1.
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
N Engl J Med
; 390(15): 1359-1371, 2024 Apr 18.
Article
in English
| MEDLINE | ID: mdl-38631003
2.
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial.
Lancet
; 402(10407): 1043-1051, 2023 09 23.
Article
in English
| MEDLINE | ID: mdl-37524096
3.
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
N Engl J Med
; 385(8): 683-694, 2021 08 19.
Article
in English
| MEDLINE | ID: mdl-34407342
4.
Localised non-metastatic sarcomatoid renal cell carcinoma: a 31-year externally verified study.
BJU Int
; 133(2): 169-178, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37589200
5.
Cardiovascular Implications of Vascular Endothelial Growth Factor Inhibition Among Adolescents/Young Adults in ECOG-ACRIN E2805.
J Natl Compr Canc Netw
; 21(7): 725-731.e1, 2023 07.
Article
in English
| MEDLINE | ID: mdl-37433436
6.
Disease-free survival as a predictor of overall survival in localized renal cell carcinoma following initial nephrectomy: A retrospective analysis of Surveillance, Epidemiology and End Results-Medicare datac.
Int J Urol
; 30(3): 272-279, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36788716
7.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 23(9): 1133-1144, 2022 09.
Article
in English
| MEDLINE | ID: mdl-36055304
8.
ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study.
Oncologist
; 27(6): 453-461, 2022 06 08.
Article
in English
| MEDLINE | ID: mdl-35373299
9.
Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805.
BJU Int
; 129(6): 718-722, 2022 06.
Article
in English
| MEDLINE | ID: mdl-34480522
10.
Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.
J Urol
; 203(4): 684-689, 2020 04.
Article
in English
| MEDLINE | ID: mdl-31596672
11.
Association between age and sex and mortality after adjuvant therapy for renal cancer.
Cancer
; 125(10): 1637-1644, 2019 05 15.
Article
in English
| MEDLINE | ID: mdl-30620389
12.
Patterns of Relapse and Implications for Post-Nephrectomy Surveillance in Patients with High Risk Nonclear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 3 ECOG-ACRIN E2805 Trial.
J Urol
; 201(1): 62-68, 2019 01.
Article
in English
| MEDLINE | ID: mdl-30130544
13.
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
Future Oncol
; 15(15): 1683-1695, 2019 May.
Article
in English
| MEDLINE | ID: mdl-30968729
14.
A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours.
Br J Cancer
; 119(10): 1200-1207, 2018 11.
Article
in English
| MEDLINE | ID: mdl-30318516
15.
Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial.
J Urol
; 199(1): 53-59, 2018 01.
Article
in English
| MEDLINE | ID: mdl-28728992
16.
Nivolumab Plus Ipilimumab with Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma.
J Vasc Interv Radiol
; 34(6): 1089-1091.e1, 2023 06.
Article
in English
| MEDLINE | ID: mdl-36804297
17.
Longitudinal and dynamic measurement invariance of the FACIT-Fatigue scale: an application of the measurement model of derivatives to ECOG-ACRIN study E2805.
Qual Life Res
; 27(6): 1589-1597, 2018 06.
Article
in English
| MEDLINE | ID: mdl-29508208
18.
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Lancet
; 387(10032): 2008-16, 2016 May 14.
Article
in English
| MEDLINE | ID: mdl-26969090
19.
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America.
Prostate
; 75(8): 836-44, 2015 Jun.
Article
in English
| MEDLINE | ID: mdl-25683285
20.
Adjuvant therapy for renal cell carcinoma: past, present, and future.
Oncologist
; 19(8): 851-9, 2014 Aug.
Article
in English
| MEDLINE | ID: mdl-24969163